Sign in

Trial result ·

Recombinant hCG versus dual triggering for final oocyte maturation in ICSI cycles among poor responders with endometriosis.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This double-blind trial compared ways to trigger egg maturation in ICSI cycles. The women had endometriosis and a poor ovarian response. In all, 152 women were randomized. One group got rhCG plus placebo (n = 76). The other got rhCG plus a GnRH agonist, called dual triggering (n = 76). Of these, 128 women completed the protocol through embryo transfer. The main outcome was the number of mature (MII) eggs retrieved.

What they found

Dual triggering gave significantly more MII eggs. The mean was 6.53 against 4.14. It also gave more Grade A embryos, at 0.66 against 0.37. Chemical pregnancy rates were significantly higher with dual triggering. Clinical pregnancy rates were also significantly higher. The risk ratio for clinical pregnancy was 3.54. The range was 1.64-7.62. Intention-to-treat analyses agreed.

What it means for patients

The authors say dual triggering improved egg maturity, embryo quality and clinical pregnancy. This was in poor responders with endometriosis. They say larger multicenter trials are warranted.

Why it is not certain yet

This was one trial. Only 128 of the 152 women completed the protocol through embryo transfer. The authors say larger multicenter trials are needed to confirm the results. The abstract gives no birth results.

Source

Recombinant hCG versus dual triggering for final oocyte maturation in ICSI cycles among poor responders with endometriosis.

PubMed · PMID 42782241

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Endometriosis publications